Logo image of OTIC

OTONOMY INC (OTIC) Stock Fundamental Analysis

USA - NASDAQ:OTIC - US68906L1052 - Common Stock

0.077 USD
-0.01 (-11.19%)
Last: 12/22/2022, 8:00:02 PM
0.083 USD
+0.01 (+7.79%)
After Hours: 12/22/2022, 8:00:02 PM
Fundamental Rating

1

Overall OTIC gets a fundamental rating of 1 out of 10. We evaluated OTIC against 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of OTIC have multiple concerns. OTIC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year OTIC has reported negative net income.
In the past year OTIC has reported a negative cash flow from operations.
OTIC Yearly Net Income VS EBIT VS OCF VS FCFOTIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

OTIC has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTIC Yearly ROA, ROE, ROICOTIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OTIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTIC Yearly Profit, Operating, Gross MarginsOTIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -10K -20K -30K -40K

2

2. Health

2.1 Basic Checks

OTIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OTIC has been increased compared to 1 year ago.
The debt/assets ratio for OTIC is higher compared to a year ago.
OTIC Yearly Shares OutstandingOTIC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
OTIC Yearly Total Debt VS Total AssetsOTIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

OTIC has an Altman-Z score of -16.93. This is a bad value and indicates that OTIC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.93, OTIC is not doing good in the industry: 90.99% of the companies in the same industry are doing better.
OTIC has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, OTIC is in line with its industry, outperforming 49.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -16.93
ROIC/WACCN/A
WACC10.41%
OTIC Yearly LT Debt VS Equity VS FCFOTIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

OTIC has a Current Ratio of 1.74. This is a normal value and indicates that OTIC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of OTIC (1.74) is worse than 75.23% of its industry peers.
OTIC has a Quick Ratio of 1.74. This is a normal value and indicates that OTIC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of OTIC (1.74) is worse than 69.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
OTIC Yearly Current Assets VS Current LiabilitesOTIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.94% over the past year.
The Revenue for OTIC has decreased by -100.00% in the past year. This is quite bad
OTIC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.73% yearly.
EPS 1Y (TTM)4.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-44.97%
Revenue growth 5Y-28.73%
Sales Q2Q%N/A

3.2 Future

OTIC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.08% yearly.
Based on estimates for the next years, OTIC will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y3.04%
EPS Next 2Y10.42%
EPS Next 3Y-0.66%
EPS Next 5Y2.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OTIC Yearly Revenue VS EstimatesOTIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 500K 1M
OTIC Yearly EPS VS EstimatesOTIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OTIC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OTIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTIC Price Earnings VS Forward Price EarningsOTIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTIC Per share dataOTIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.42%
EPS Next 3Y-0.66%

0

5. Dividend

5.1 Amount

OTIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OTONOMY INC

NASDAQ:OTIC (12/22/2022, 8:00:02 PM)

After market: 0.083 +0.01 (+7.79%)

0.077

-0.01 (-11.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2022-11-10/amc
Earnings (Next)02-27 2023-02-27
Inst Owners0%
Inst Owner Change0%
Ins Owners10.54%
Ins Owner Change0%
Market Cap4.40M
Analysts77.78
Price Target9.18 (11822.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.99%
Min EPS beat(2)6.86%
Max EPS beat(2)7.12%
EPS beat(4)3
Avg EPS beat(4)2.53%
Min EPS beat(4)-7.44%
Max EPS beat(4)7.12%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.52%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS0
BVpS0.37
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z -16.93
F-Score2
WACC10.41%
ROIC/WACCN/A
Cap/Depr(3y)35.87%
Cap/Depr(5y)49.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
EPS Next Y3.04%
EPS Next 2Y10.42%
EPS Next 3Y-0.66%
EPS Next 5Y2.08%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-44.97%
Revenue growth 5Y-28.73%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-8.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.44%
OCF growth 3YN/A
OCF growth 5YN/A